Study of the fibrinolytic systems in patients with dilated cardiomyopathy;Estudio del sistema fibrinolítico en pacientes con miocardiopatía dilatada

Sangre

Volumn 41, Issue 5, 1996, Pages 351-355

  Fernández, Pascual ^a   Marín, Francisco ^b   Marco, Pascual ^a,c   Roldán, Vanessa ^a   García, M Carmen ^a   Martínez, J Gabriel ^b   Sogorb, Francisco ^b   Calatayud, Ramiro ^a  

^a Unidad de Trombosis y Hemostasia

^b UNIVERSITY OF ALICANTE   (Spain)

^c Alicante General Hospital   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ALCOHOLIC CARDIOMYOPATHY; ARTICLE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONGESTIVE CARDIOMYOPATHY; DRUG EFFECT; FEMALE; FIBRINOLYSIS; HEART ATRIUM FIBRILLATION; HEART DISEASE; HOSPITALIZATION; HUMAN; LIGATION; MALE; MIDDLE AGED; RISK FACTOR; THROMBOEMBOLISM; THROMBOSIS;

ADULT; ANTICOAGULANTS; ATRIAL FIBRILLATION; CARDIOMYOPATHY, ALCOHOLIC; CARDIOMYOPATHY, DILATED; CONSTRICTION; FEMALE; FIBRINOLYSIS; FIBRINOLYTIC AGENTS; HEART DISEASES; HUMANS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; RISK FACTORS; SEVERITY OF ILLNESS INDEX; THROMBOEMBOLISM; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0030253833     PISSN: 00364355     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Jung SC, Wilensky RL, Zeiter J, Sawada S. Thrombin activation in dilated cardiomyopathy. JACC 1993; 21 : 311A.
2. Kyrie PA, Korninger C, Grössinger H, Glogar D. Lechner K, Niessner H, et al. Prevention of arterial and pulmonary embolism by oral anticoagulants in patients with dilated cardiomyopathy. Thromb Haemost 1985; 54: 521-523.
3. Fuster V, Gersh BJ, Giulani ER, Tajik AJ, Brandenburg RO, Frye RL. The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol 1981; 47: 525-531.
4. Falk RH, Foster E, Coats M Ventricular thrombi and thromboembolism in dilated cardiomyopathy: a prospective follow-up study. Am Heart J 1992; 123: 136-142.
5. Yanamoto K, Ikeda U, Furuhashi K, Irokawa M, Nakayama T, Shimada K. The coagulation system is activated in idiopathic cardiomyopathy. JACC 1995; 25: 1634-1640.
6. Roberts WC, Siegel RJ, McManus BM. Idiopathic dilated cardiomyopathy: analysis of 152 necropsy patients. Am J Cardiol 1987; 60: 1340-1355.
7. The Criteria Committee of the New York Heart Association: Diseases of the heart and blood vessels; nomenclatura and criteria for diagnosis, 6th ed. Boston: Little, Brown and Co. 1964.
8. Bauer KA. Hypercoagulate states. En: Hoffman R, Beur EJ, Shatil SJ, Furie B, Cohen HJ, Silberstein LE (eds). Hematology. Basic Principles and Clinical Practice. 2th ed New York: Churchill Livingstone 1995; 1781-1795.
9. Galve E Anticuerpos antifosfolípido y corazón.Rev Esp Cardiol 1992; 45: 615-617.
10. Murphy JJ, Leach IH. Findings at necropsy in the heart of a patient with anticardiolipin syndrome. Br Heart J 1989, 62: 61-64.
11. Kaplan SD, Chartash EK, Pizzarello RA, Furie RA. Cardiac manifestations of the antiphospholipid syndrome. Am Heart J 1992; 124: 1331-1338.
12. Rocha E, Paramo JA, Hermida J, Panizo C. Alteraciones de la fibrinolisis, arterioesclerosis y trombosis coronaria. Sangre 1994; 39 (supl 1): 224-230.
13. Wiman B. Plasminogen activator inhibitor 1 (PAI-1) in plasma: its rol in thrombotic disease. Thromb Haemost 1995; 74: 71-76.
14. Ridker PM, Vaughan DE, Stampfer MK, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocadial infarction. Lancet 1993; 341: 1165-1168.
15. Ridker PM, Hennekens CH, Stampfer MK, Manson JE, Vaughan DE. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet 1994, 343: 940-943.